Successful treatment with yttrium-90 microspheres in a metastatic breast cancer patient and sclerosing cholangitis.
Aurélie LouvetCédric van MarckePhilippe D'AbadieEmmanuel SerontPublished in: Future science OA (2021)
Breast cancer is the most common malignancy occurring in women worldwide. More than 90% of patients present with localized disease are treated with curative intent; however, recurrence can occur with development of metastatic lesions. Frequently associated with extra-hepatic lesions, localized treatments (surgery or stereotaxic body radiotherapy) are rarely proposed in liver lesions. 90Y radioembolization has extensively been evaluated in colorectal cancer, but its role in breast cancer with isolated liver metastases remains largely unknown. Pre-existing liver diseases are known risk factors for 90Y induced liver toxicity. Not considered as an excluding factor for this treatment, data are limited regarding its safe use with cholangitis. We report a successful control of liver metastases by 90Y radioembolization in a breast cancer patient.
Keyphrases
- liver metastases
- metastatic breast cancer
- end stage renal disease
- newly diagnosed
- case report
- ejection fraction
- prognostic factors
- breast cancer risk
- minimally invasive
- squamous cell carcinoma
- chronic kidney disease
- small cell lung cancer
- early stage
- radiation therapy
- coronary artery bypass
- multidrug resistant
- high glucose
- peritoneal dialysis
- oxidative stress
- pregnant women
- type diabetes
- coronary artery disease
- patient reported outcomes
- high resolution